《新股消息》藥明巨諾(02126.HK)公開發售超購448倍 一手中籤率僅5%
由藥明康德(02359.HK)及美國醫藥研發平台Juno共同投資、內地臨床及臨床前階段細胞治療公司藥明巨諾(02126.HK)公布招股結果,計劃發行9,769.2萬股,公開發售錄超購448.42倍,據國際發售初步提呈發售的發售股份已獲超額認購(相當國際發售初步可供認購的發售股份總數約28.5倍),經重新分配後,公開發售股數增至50%,一手500股中籤率為5%
每股發售價定於23.8元,為上限定價(招股價介乎20至23.8元)。該股將於明日(3日)掛牌上市。高盛及瑞銀為聯席保薦人。
該股引入10名基石投資者,共認購4,884萬股份,包括Rock Springs Capital、橡樹資本管理公司等各認購651.2萬股;高瓴基金、太平資產管理等各認購325.6萬股。
公司預計集資淨額為21.97億元,當中30%將用於有關relma-cel的研發活動;10%用於建立專門的內部銷售與營銷團隊將relma-cel推廣至中國各地;6%用於有關JWCAR129的研發活動;28%用於有關其他臨床前候選產品;4%用於透過行使Acepodia選擇權獲得Acepodia許可;12%將用於新潛在收購及引進授權機會;餘下10%為營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.